

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SHANGHAI JUNSHI BIOSCIENCES CO., LTD.\***

**上海君實生物醫藥科技股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 1877)**

**VOLUNTARY ANNOUNCEMENT –  
INHIBITOR JS111 FOR EGFR exon 20 INSERTION AND OTHER UNCOMMON  
MUTATIONS RECEIVED THE CLINICAL TRIAL APPROVAL**

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.\* (上海君實生物醫藥科技股份有限公司) (the “**Company**”) on a voluntary basis. Reference is also made to the overseas regulatory announcement of the Company dated 26 April 2021.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, Suzhou Junjing Biomedical Technology Co., Ltd.\* (蘇州君境生物醫藥科技有限公司), a company jointly invested by the Company and Wigen Biomedicine Technology (Shanghai) Co., Ltd., has received the Clinical Trial Approval (《藥物臨床試驗批准通知書》) issued by the National Medical Products Administration. The investigational new drug application for the uncommon EGFR mutations inhibitor AP-L1898 capsules (product code: “JS111”) has been approved. Relevant information is as follows:

**ABOUT JS111**

Drug name: AP-L1898 capsules

Application matter: Registration of Domestic Production of Pharmaceutical Product

Acceptance No.: CXHL2100122, CXHL2100123

Applicant: Suzhou Junjing Biomedical Technology Co., Ltd.\* (蘇州君境生物醫藥科技有限公司)

Review conclusion: According to the Drug Administration Law of the People's Republic of China and relevant regulations, upon review, the AP-L1898 capsules accepted for application on 20 February 2021 fulfils the relevant requirements regarding drug registration and is approved to conduct clinical trials for advanced non-small cell lung cancer.

JS111 is a small molecule inhibitor that effectively inhibits uncommon EGFR (epidermal growth factor receptor) mutations. The uncommon EGFR mutations account for about 10% among all EGFR mutations, including EGFR exon 20 insertion, T790M point mutation and complex mutations, as well as other point mutations and sequence repeat mutations between exons 18 and 21 represented by G719X. Due to the limited clinical benefits from existing EGFR-TKI, chemotherapy and immunotherapy for patients with EGFR exon 20 insertion or other uncommon EGFR mutations in non-small cell lung cancer, patients have urgent demand for clinical treatments. Pre-clinical data showed that JS111 maintains the activity of inhibition for the common EGFR mutations such as T790M and selection of wild-type EGFR, while overcoming the insensitivity of the third-generation EGFR inhibitor for exon 20 insertion and other uncommon EGFR mutations. The development of JS111 is expected to bring new treatments for cancer patients with EGFR exon 20 insertion mutation and other uncommon EGFR mutations. The Company has the world-wide exclusive production rights, licensed production rights and sales rights for JS111. Further details are set forth in the announcement published by the Company on 16 September 2020.

## **RISK WARNING**

Due to the high-tech, high-risk and high-value-added characteristics of pharmaceutical products, there are substantial risks and uncertainties in the process of drug research, development and commercialization. These many stages make it susceptible to uncertainties and therefore, investors are advised to make cautious decisions and pay careful attention to investment risks. The Company will actively pursue the above research and development projects and fulfil its information disclosure obligations regarding the subsequent progress of the projects in a timely manner and in strict accordance with relevant regulations.

By order of the Board  
**Shanghai Junshi Biosciences Co., Ltd.\***  
**Mr. Xiong Jun**  
Chairman

Shanghai, the PRC, 26 April 2021

*As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing and Dr. Yao Sheng as executive Directors; Dr. Wu Hai, Mr. Tang Yi, Mr. Li Cong, Mr. Yi Qingqing and Mr. Lin Lijun as non-executive Directors; and Dr. Chen Lieping, Mr. Qian Zhi, Mr. Zhang Chun, Dr. Jiang Hualiang and Dr. Roy Steven Herbst as independent non-executive Directors.*

\* For identification purpose only